Alliance Pharma Regulatory News (APH)

10 May 2006 07:00

Alliance Pharma PLC10 May 2006 For immediate release 10 May 2006 ALLIANCE PHARMA PLC ("Alliance Pharma" or "the Company") Placing to raise £2.5 million Alliance Pharma plc (AIM: APH), a speciality pharmaceutical company, is pleasedto announce that it has conditionally placed 14,705,883 new ordinary shares of1p each in the capital of the Company ("Ordinary Shares") at a price of 17p pershare, raising a total of £2.5 million (before expenses) for the Company.Application has been made to AIM for the new shares to be admitted to trading,which is expected to commence on 15 May 2006. The proceeds of the placing will be used for general corporate purposes. John Dawson, Alliance Pharma's Chief Executive, commented: "I am delighted by the support of new and existing investors in thisfundraising, the proceeds of which will provide additional finance as theCompany moves closer to the regulatory filing of key pipeline products includingPosidorm for sleep disorders." The placing has been undertaken by Numis Securities Limited ("Numis") and isconditional on the placing agreement between Numis and the Company becomingunconditional and not being terminated on or before 15 May 2006 (or such laterdate as Numis and the Company may agree, being not later than 30 May 2006). Thenew Ordinary Shares will rank pari passu in all respects with the existingOrdinary Shares in issue. For further information: Alliance Pharma plc +44 (0) 1249 466966 John Dawson, Chief Executive Maddy Scott, Finance Director www.alliancepharma.co.uk Buchanan Communications +44 (0) 20 7466 5000 Mark Court/Lisa Baderoon/Rebecca Dietrich Notes to editors About Alliance PharmaAlliance Pharma, founded in 1996, is an AIM listed speciality pharmaceuticalcompany based in Chippenham, Wiltshire, UK. The company has a strong trackrecord of acquiring the rights to established niche brands and owns, or shares,the rights to 30 branded pharmaceutical products and continues to exploreopportunities to expand the range. Alliance Pharma's products are prescribed in the treatment of a wide range ofconditions and include brands used in periodontitis (a serious gum disease), theprevention of heart disease, in Parkinson's disease, in nutrition, in nasalinfections, in the treatment of dermatological conditions and in childbirth.Alliance Pharma's sales are mainly prescription driven. Its products aredistributed to hospitals directly and to UK and international pharmaceuticalwholesalers which service both hospital and retail pharmacies with theirprescription requirements. Alliance Pharma is also developing Posidorm for sleep disorders and Isprelor forthe induction of labour. Alliance Pharma joined the AIM market of the London Stock Exchange in December2003 and trades under the symbol APH. This information is provided by RNS The company news service from the London Stock Exchange